Abiopharma

🔍 Brandon-Gordon Andrew Mark (Director)

Company: Paramount Skydance Corp (PSKY)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Acquired 200,000 shares of Class B common stock (Direct)
  Date: 2026-05-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 420,817.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 101,760 shares of Class B common stock at $10.76 per share (Direct)
  Date: 2026-05-07 | Code: F | equity_swap_involved: 0 | shares_owned_after: 319,057.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 200,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,400,000.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: The shares identified in Table I were issued on May 7, 2026, upon vesting of an installment of Restricted Stock Units ("RSUs") identified in Table II, which were initially granted on August 7, 2025 and generally vest in equal quarterly installments over a five-year period. On May 7, 2026, the closing price of the Class B common stock on The NASDAQ Global Select Market was $10.76 per share.
• F2: These shares were withheld by the Issuer to satisfy tax liability incident to the vesting of, and delivery of shares underlying, the RSUs, and were not actually sold or otherwise disposed of in an open-market transaction.